Overview
NICE is unable to make a recommendation on anifrolumab (Saphnelo) for active autoantibody-positive systemic lupus erythematosus. This is because AstraZeneca did not provide an evidence submission.
Last reviewed: 8 June 2022
Next review: We will review this decision if the company decides to make a submission.